Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine

Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal malignancy, with an average 5-year survival rate of 9% (Siegel RL, Miller KD, Jemal A. Ca Cancer J Clin. 2019;69(1):7-34). The steady increase in mortality rate indicates limited efficacy of the conventional regimen. The heterogeneity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yiqi, Yang, Gang, Huang, Hua, Fu, Ziyao, Cao, Zhe, Zheng, Lianfang, You, Lei, Zhang, Taiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783994/
https://www.ncbi.nlm.nih.gov/pubmed/33402215
http://dx.doi.org/10.1186/s13046-020-01787-5
_version_ 1783632213896593408
author Yu, Yiqi
Yang, Gang
Huang, Hua
Fu, Ziyao
Cao, Zhe
Zheng, Lianfang
You, Lei
Zhang, Taiping
author_facet Yu, Yiqi
Yang, Gang
Huang, Hua
Fu, Ziyao
Cao, Zhe
Zheng, Lianfang
You, Lei
Zhang, Taiping
author_sort Yu, Yiqi
collection PubMed
description Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal malignancy, with an average 5-year survival rate of 9% (Siegel RL, Miller KD, Jemal A. Ca Cancer J Clin. 2019;69(1):7-34). The steady increase in mortality rate indicates limited efficacy of the conventional regimen. The heterogeneity of PDAC calls for personalized treatment in clinical practice, which requires the construction of a preclinical system for generating patient-derived models. Currently, the lack of high-quality preclinical models results in ineffective translation of novel targeted therapeutics. This review summarizes applications of commonly used models, discusses major difficulties in PDAC model construction and provides recommendations for integrating workflows for precision medicine.
format Online
Article
Text
id pubmed-7783994
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77839942021-01-14 Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine Yu, Yiqi Yang, Gang Huang, Hua Fu, Ziyao Cao, Zhe Zheng, Lianfang You, Lei Zhang, Taiping J Exp Clin Cancer Res Review Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal malignancy, with an average 5-year survival rate of 9% (Siegel RL, Miller KD, Jemal A. Ca Cancer J Clin. 2019;69(1):7-34). The steady increase in mortality rate indicates limited efficacy of the conventional regimen. The heterogeneity of PDAC calls for personalized treatment in clinical practice, which requires the construction of a preclinical system for generating patient-derived models. Currently, the lack of high-quality preclinical models results in ineffective translation of novel targeted therapeutics. This review summarizes applications of commonly used models, discusses major difficulties in PDAC model construction and provides recommendations for integrating workflows for precision medicine. BioMed Central 2021-01-05 /pmc/articles/PMC7783994/ /pubmed/33402215 http://dx.doi.org/10.1186/s13046-020-01787-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Yu, Yiqi
Yang, Gang
Huang, Hua
Fu, Ziyao
Cao, Zhe
Zheng, Lianfang
You, Lei
Zhang, Taiping
Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
title Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
title_full Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
title_fullStr Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
title_full_unstemmed Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
title_short Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
title_sort preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783994/
https://www.ncbi.nlm.nih.gov/pubmed/33402215
http://dx.doi.org/10.1186/s13046-020-01787-5
work_keys_str_mv AT yuyiqi preclinicalmodelsofpancreaticductaladenocarcinomachallengesandopportunitiesintheeraofprecisionmedicine
AT yanggang preclinicalmodelsofpancreaticductaladenocarcinomachallengesandopportunitiesintheeraofprecisionmedicine
AT huanghua preclinicalmodelsofpancreaticductaladenocarcinomachallengesandopportunitiesintheeraofprecisionmedicine
AT fuziyao preclinicalmodelsofpancreaticductaladenocarcinomachallengesandopportunitiesintheeraofprecisionmedicine
AT caozhe preclinicalmodelsofpancreaticductaladenocarcinomachallengesandopportunitiesintheeraofprecisionmedicine
AT zhenglianfang preclinicalmodelsofpancreaticductaladenocarcinomachallengesandopportunitiesintheeraofprecisionmedicine
AT youlei preclinicalmodelsofpancreaticductaladenocarcinomachallengesandopportunitiesintheeraofprecisionmedicine
AT zhangtaiping preclinicalmodelsofpancreaticductaladenocarcinomachallengesandopportunitiesintheeraofprecisionmedicine

Ejemplares similares